Systemic corticosteroids in coronavirus disease 2019 (COVID‐19)‐related smell dysfunction: an international view. Issue 7 (16th March 2021)

• Record Type: Journal Article
• Authors: Huart, Caroline; Philpott, Carl M.; Altundag, Aytug; Fjaeldstad, Alexander W.; Frasnelli, Johannes; Gane, Simon; Hsieh, Julien W.; Holbrook, Eric H.; Konstantinidis, Iordanis; Landis, Basile N.; Macchi, Alberto; Mueller, Christian A.; Negoias, Simona; Pinto, Jayant M.; Poletti, Sophia C.; Ramakrishnan, Vijay R.; Rombaux, Philippe; Vodicka, Jan; Welge‐Lüessen, Antje; Whitcroft, Katherine L.; Hummel, Thomas
• Is Part Of: International forum of allergy & rhinology. Volume 11:Issue 7(2021)
• Page Start: 1041
• Page End: 1046
• Publication Date: 2021-03-16
• Subjects: corticosteroids -- COVID‐19 -- olfaction disorder -- SARS‐CoV‐2 -- smell; 617.51005
• DOI: 10.1002/alr.22788
• Languages: English
• ISSNs: 2042-6976

Abstract

Summary: The frequent association between coronavirus disease 2019 (COVID‐19) and olfactory dysfunction is creating an unprecedented demand for a treatment of the olfactory loss. Systemic corticosteroids have been considered as a therapeutic option. However, based on current literature, we call for caution using these treatments in early COVID‐19–related olfactory dysfunction because: (1) evidence supporting their usefulness is weak; (2) the rate of spontaneous recovery of COVID‐19–related olfactory dysfunction is high; and (3) corticosteroids have well‐known potential adverse effects. We encourage randomized placebo‐controlled trials investigating the efficacy of systemic steroids in this indication and strongly emphasize to initially consider smell training, which is supported by a robust evidence base and has no known side effects.